Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLE-400 topical gel in Notalgia Paresthetica
NCT06262607Phase 2Completed
- Sponsor
- Clexio Biosciences
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in notalgia paresthetica (NP) comparing CLE-400 (Detomidine topical gel) with Vehicle (2 arms). Primary endpoint: Worst Itch-Numeric Rating Scale at 4 weeks. Started Jan 2024; status: completed.
02
Drugs
detomidine
03
Conditions
notalgia paresthetica (NP)
Beyond the preview
Go deeper on NCT06262607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06262607.